<?xml version="1.0" encoding="UTF-8"?><html>
   <div tagx="ui">s13063-015-0561-0</div>
   <div tagx="ji">1745-6215</div>
   <head>
      <div tagx="dochead">Study protocol</div>
      <div tagx="bibl">
         <div tagx="title">
            <p>Effects and cost-effectiveness of pharmacogenetic screening for CYP2D6 among older
               adults starting therapy with nortriptyline or venlafaxine: study protocol for a pragmatic
               randomized controlled trial (CYSCEtrial)
            </p>
         </div>
         <ul tagx="aug">
            <li tagx="au">
               <span tagx="snm">Berm</span>
               <span tagx="mnm">JJ</span>
               <span tagx="fnm">Elizabeth</span>
               <span tagx="insr"></span>
               <a href="e.j.j.berm@rug.nl">e.j.j.berm@rug.nl</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Hak</span>
               <span tagx="fnm">Eelko</span>
               <span tagx="insr"></span>
               <span tagx="insr"></span>
               <a href="e.hak@rug.nl">e.hak@rug.nl</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Postma</span>
               <span tagx="fnm">Maarten</span>
               <span tagx="insr"></span>
               <span tagx="insr"></span>
               <a href="m.j.postma@rug.nl">m.j.postma@rug.nl</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Boshuisen</span>
               <span tagx="fnm">Marjolein</span>
               <span tagx="insr"></span>
               <a href="m.boshuisen@lentis.nl">m.boshuisen@lentis.nl</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Breuning</span>
               <span tagx="fnm">Laura</span>
               <span tagx="insr"></span>
               <a href="l.breuning@rvagroep.nl">l.breuning@rvagroep.nl</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Brouwers</span>
               <span tagx="mnm">RBJ</span>
               <span tagx="fnm">Jacobus</span>
               <span tagx="insr"></span>
               <span tagx="insr"></span>
               <a href="jrbjbrouwers@stbebo.nl">jrbjbrouwers@stbebo.nl</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Dhondt</span>
               <span tagx="fnm">Ton</span>
               <span tagx="insr"></span>
               <a href="a.dhondt@ggz-nhn.nl">a.dhondt@ggz-nhn.nl</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Jansen</span>
               <span tagx="mnm">AF</span>
               <span tagx="fnm">Paul</span>
               <span tagx="insr"></span>
               <a href="p.a.f.jansen@umcutrecht.nl">p.a.f.jansen@umcutrecht.nl</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Kok</span>
               <span tagx="mi">M</span>
               <span tagx="fnm">Rob</span>
               <span tagx="insr"></span>
               <a href="r.kok@parnassia.nl">r.kok@parnassia.nl</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Maring</span>
               <span tagx="mi">G</span>
               <span tagx="fnm">Jan</span>
               <span tagx="insr"></span>
               <a href="maring@noorderboog.nl">maring@noorderboog.nl</a>
            </li>
            <li tagx="au">
               <span tagx="snm">van Marum</span>
               <span tagx="fnm">Rob</span>
               <span tagx="insr"></span>
               <span tagx="insr"></span>
               <a href="r.v.marum@jbz.nl">r.v.marum@jbz.nl</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Mulder</span>
               <span tagx="fnm">Hans</span>
               <span tagx="insr"></span>
               <a href="hans.mulder@wza.nl">hans.mulder@wza.nl</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Voshaar</span>
               <span tagx="mi">C Oude</span>
               <span tagx="fnm">Richard</span>
               <span tagx="insr"></span>
               <a href="r.c.oude.voshaar@umcg.nl">r.c.oude.voshaar@umcg.nl</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Risselada</span>
               <span tagx="mi">J</span>
               <span tagx="fnm">Arne</span>
               <span tagx="insr"></span>
               <a href="arne.risselada@wza.nl">arne.risselada@wza.nl</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Venema</span>
               <span tagx="fnm">Harry</span>
               <span tagx="insr"></span>
               <a href="harry.venema@ggzfriesland.nl">harry.venema@ggzfriesland.nl</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Vleugel</span>
               <span tagx="fnm">Liesbeth</span>
               <span tagx="insr"></span>
               <a href="l.vleugel@ggzingeest.nl">l.vleugel@ggzingeest.nl</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Wilffert</span>
               <span tagx="fnm">Bob</span>
               <span tagx="insr"></span>
               <span tagx="insr"></span>
               <a href="b.wilffert@rug.nl">b.wilffert@rug.nl</a>
            </li>
         </ul>
         <ul tagx="insg">
            <li tagx="ins">
               <p>Groningen Institute of Pharmacy, University of Groningen, Unit of Pharmacotherapy
                  &amp; Pharmaceutical Care, Antonius Deusinglaan 1, Groningen, 9713AV, The Netherlands
               </p>
            </li>
            <li tagx="ins">
               <p>Groningen Institute of Pharmacy, University of Groningen, Unit of Pharmacoepidemiology
                  &amp; Pharmacoeconomics, Groningen, The Netherlands
               </p>
            </li>
            <li tagx="ins">
               <p>Department of Epidemiology, University Medical Center Groningen, Groningen, The Netherlands</p>
            </li>
            <li tagx="ins">
               <p>Lentis, Dignis, Groningen, The Netherlands</p>
            </li>
            <li tagx="ins">
               <p>Departement of Old Age and Clinical Psychiatry, Reinier van Arkel Group, ‘s-Hertogenbosch,
                  The Netherlands
               </p>
            </li>
            <li tagx="ins">
               <p>Department of Geriatric Medicine and Expertise Centere Pharmacotherapy in Old Persons,
                  UMC Utrecht, Utrecht, The Netherlands
               </p>
            </li>
            <li tagx="ins">
               <p>Department of Old-age Psychiatry, GGZ-Noord Holland Noord, Heerhugowaard, The Netherlands</p>
            </li>
            <li tagx="ins">
               <p>Department of Old Age, Parnassia Psychiatric Institute, The Hague, The Netherlands</p>
            </li>
            <li tagx="ins">
               <p>Laboratory for Drug Analysis &amp; Toxicology, Diaconessen Hospital Meppel &amp; Bethesda
                  Hospital Hoogeveen, Meppel, The Netherlands
               </p>
            </li>
            <li tagx="ins">
               <p>Department of Geriatric Medicine, Jeroen Bosch Hospital, ‘s Hertogenbosch, The Netherlands</p>
            </li>
            <li tagx="ins">
               <p>Department of General Practice &amp; Elderly Care Medicine, VU University, Amsterdam,
                  The Netherlands
               </p>
            </li>
            <li tagx="ins">
               <p>Clinical Pharmacy, Wilhelmina Hospital Assen, Assen, The Netherlands</p>
            </li>
            <li tagx="ins">
               <p>University of Groningen, University Medical Center Groningen, University Center for
                  Psychiatry, Groningen, The Netherlands
               </p>
            </li>
            <li tagx="ins">
               <p>Department of Old Age Psychiatry, GGZ Friesland, Leeuwarden, The Netherlands</p>
            </li>
            <li tagx="ins">
               <p>Department of Old Age Psychiatry, GGZ inGeest, Haarlem, The Netherlands</p>
            </li>
            <li tagx="ins">
               <p>Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen,
                  Groningen, The Netherlands
               </p>
            </li>
         </ul>
         <span tagx="source">Trials</span>
         <span tagx="issn">1745-6215</span>
         <span tagx="pubdate">2015</span>
         <span tagx="volume">16</span>
         <span tagx="issue">1</span>
         <span tagx="fpage">37</span>
         <a href="http://www.trialsjournal.com/content/16/1/37">http://www.trialsjournal.com/content/16/1/37</a>
         <div tagx="xrefbib">
            <div tagx="pubidlist">
               <span tagx="pubid">10.1186/s13063-015-0561-0</span>
            </div>
         </div>
      </div>
      <div tagx="history">
         <span tagx="rec">
            <div tagx="date">
               <span tagx="day">15</span>
               <span tagx="month">10</span>
               <span tagx="year">2014</span>
            </div>
         </span>
         <span tagx="acc">
            <div tagx="date">
               <span tagx="day">12</span>
               <span tagx="month">1</span>
               <span tagx="year">2015</span>
            </div>
         </span>
         <span tagx="pub">
            <div tagx="date">
               <span tagx="day">31</span>
               <span tagx="month">1</span>
               <span tagx="year">2015</span>
            </div>
         </span>
      </div>
      <div tagx="cpyrt">
         <span tagx="year">2015</span>
         <div tagx="collab">Berm et al.; licensee BioMed Central.</div>
         <div tagx="note">This is an Open Access article distributed under the terms of the Creative Commons
            Attribution License (
            <a href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</a>), which permits unrestricted use, distribution, and reproduction in any medium, provided
            the original work is properly credited. The Creative Commons Public Domain Dedication
            waiver (
            <a href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</a>) applies to the data made available in this article, unless otherwise stated.
         </div>
      </div>
      <ul tagx="kwdg">
         <li tagx="kwd">CYP2D6</li>
         <li tagx="kwd">Pharmacogenetics</li>
         <li tagx="kwd">Depression</li>
         <li tagx="kwd">Nortriptyline</li>
         <li tagx="kwd">Venlafaxine</li>
      </ul>
      <div id="abstract" tag="abstract">
         <div id="">
            <div tagx="st">
               <h2>Abstract</h2>
            </div>
            <div id="">
               <div tagx="st">
                  <h3>Background</h3>
               </div>
               <p>Nortriptyline and venlafaxine are commonly used antidepressants for treatment of depression
                  in older patients. Both drugs are metabolized by the polymorphic cytochrome P450-2D6
                  (CYP2D6) enzyme and guidelines for dose adaptations based on the 
                  <i>CYP2D6</i> genotype have been developed. The CYP2D6 Screening Among Elderly (CYSCE) trial is
                  designed to address the potential health and economic value of genotyping for 
                  <i>CYP2D6</i> in optimizing dose-finding of nortriptyline and venlafaxine.
               </p>
            </div>
            <div id="">
               <div tagx="st">
                  <h3>Methods/Design</h3>
               </div>
               <p>In a pragmatic randomized controlled trial, patients diagnosed with a major depressive
                  disorder according to the DSM-IV and aged 60 years or older will be recruited from
                  psychiatric centers across the Netherlands. After 
                  <i>CYP2D6</i> genotyping determined in peripheral blood obtained by finger-prick, patients will
                  be grouped into poor, intermediate, extensive, or ultrarapid metabolizers. Patients
                  with deviant genotype (that is poor, intermediate or ultrarapid genotype) will be
                  randomly allocated to an intervention group in which the genotype and dosing advice
                  is communicated to the treating physician, or to a control group in which patients
                  receive care as usual. Additionally, an external reference group of patients with
                  the extensive metabolizer genotype is included. Primary outcome in all groups is time
                  needed to obtain an adequate blood level of the antidepressant drug. Secondary outcomes
                  include adverse drug reactions measured by a shortened Antidepressant Side-Effects
                  Checklist (ASEC), and cost-effectiveness of the screening.
               </p>
            </div>
            <div id="">
               <div tagx="st">
                  <h3>Discussion</h3>
               </div>
               <p>Results of this trial will guide policy-making with regard to pharmacogenetic screening
                  prior to treatment with nortriptyline or venlafaxine among older patients with depression.
               </p>
            </div>
            <div id="">
               <div tagx="st">
                  <h3>Trial registration</h3>
               </div>
               <p>ClinicalTrials.gov: 
                  <a href="NCT01778907">NCT01778907</a>; registration date: 22 January 2013.
               </p>
            </div>
         </div>
      </div>
   </head>
   <div id="">
      <div tagx="st">
         <h2>Background</h2>
      </div>
      <p>Depressive disorder is a chronic disease with a considerable impact on mental and
         physical health as well as quality of life 
         <span tagx="abbrgrp">
            <span tagx="abbr">1</span>
         </span>. The 1-month prevalence of major depressive disorder (MDD) in the Dutch population
         (aged 55 to 85 years) is estimated around 2.0% 
         <span tagx="abbrgrp">
            <span tagx="abbr">2</span>
         </span>. From a meta-analysis (studies included from 1999 to 2009) a higher point prevalence
         estimation of 7.2 % has been reported for late life depression (75+ years) 
         <span tagx="abbrgrp">
            <span tagx="abbr">3</span>
         </span>. Among all mental diseases, MDD is ranked as a very disabling disease 
         <span tagx="abbrgrp">
            <span tagx="abbr">4</span>
         </span> and depressive disorders are projected to be the largest cause for disability by
         2030 in high-income countries 
         <span tagx="abbrgrp">
            <span tagx="abbr">5</span>
         </span>.
      </p>
      <p>MDD can be treated with antidepressants, which are classified into different groups:
         selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressant (TCAs) and
         others (for example,. selective serotonin-noradrenaline reuptake inhibitors (SNRIs),
         mirtazapine, monoamine oxidase inhibitors). Although overall efficacy estimates are
         virtually similar between these drug groups, adverse drug profiles differ 
         <span tagx="abbrgrp">
            <span tagx="abbr">6</span>
         </span>. Worldwide, clinical guidelines usually advise first-step treatment with an SSRI
         because of a more favorable adverse effect profile compared to other antidepressants
         (for example, fewer cardiac side-effects and often lower drug anticholinergic side-effects)
         
         <span tagx="abbrgrp">
            <span tagx="abbr">7</span>
         </span>,
         <span tagx="abbrgrp">
            <span tagx="abbr">8</span>
         </span>. If the chosen SSRI is not effective, switching to a TCA, preferably nortriptyline,
         or an SNRI, mostly venlafaxine, is an option 
         <span tagx="abbrgrp">
            <span tagx="abbr">7</span>
         </span>.
      </p>
      <p>Venlafaxine and nortriptyline are both metabolized by the polymorphic cytochrome P450
         (CYP2D6) iso-enzyme 
         <span tagx="abbrgrp">
            <span tagx="abbr">8</span>
         </span>. Its polymorphic differences are generally classified into four different phenotypes:
         poor metabolizers (PM), intermediate metabolizers (IM), extensive metabolizers (EM),
         and ultrarapid metabolizers (UM). With respect to EM, PM and IM have a decreased enzymatic
         activity whereas UM have a higher activity, which is described in more depth elsewhere
         
         <span tagx="abbrgrp">
            <span tagx="abbr">9</span>
         </span>. As a result of the variation in metabolizing capacity, as well as differences in
         gender, age, co-medication, and comorbidity among patients, different pharmacokinetics
         are observed 
         <span tagx="abbrgrp">
            <span tagx="abbr">9</span>
         </span>,
         <span tagx="abbrgrp">
            <span tagx="abbr">10</span>
         </span>. These differences can be monitored by therapeutic drug monitoring (TDM), which helps
         to find the right dosage for an individual patient. TDM of nortriptyline is ‘strongly
         recommended’ and for venlafaxine it is recommended especially during start of therapy
         
         <span tagx="abbrgrp">
            <span tagx="abbr">11</span>
         </span>. Prior and in addition to TDM, information about the metabolic CYP2D6 activity could
         further improve this dose-finding. Since it is possible to detect polymorphic differences
         of 
         <i>CYP2D6</i> based on genetic material, it is not dependent on the actual antidepressant intake
         (patient compliance) or collection time of the sample, like TDM samples are.
      </p>
      <p>For nortriptyline and venlafaxine genotyped-based dose adjustment guidelines have
         been formulated 
         <span tagx="abbrgrp">
            <span tagx="abbr">10</span>
         </span>,
         <span tagx="abbrgrp">
            <span tagx="abbr">12</span>
         </span>,
         <span tagx="abbrgrp">
            <span tagx="abbr">13</span>
         </span>. In the Netherlands, the Royal Dutch Pharmacist Association (KNMP) has made such
         guidelines available for current clinical practice 
         <span tagx="abbrgrp">
            <span tagx="abbr">14</span>
         </span>,
         <span tagx="abbrgrp">
            <span tagx="abbr">15</span>
         </span>.
      </p>
      <p>Despite the large number of studies that assessed the relationship between pharmacogenetics
         and pharmacokinetics of antidepressants, implementation of pharmacogenetic knowledge
         into clinical practice is still scarce. The hypothesized clinical improvements facilitated
         by genotype-based dose adjustments in addition to current TDM, like improved efficacy
         and prevention of adverse drug reactions, are still a matter of controversy and discussion
         
         <span tagx="abbrgrp">
            <span tagx="abbr">16</span>
         </span>,
         <span tagx="abbrgrp">
            <span tagx="abbr">17</span>
         </span>. There is a need to test this hypothesis in daily clinical practice. Therefore, we
         designed a pragmatic multicenter randomized controlled trial to determine the effects
         of a pharmacogenetic screening for 
         <i>CYP2D6</i> on the time needed to obtain adequate blood levels of nortriptyline or venlafaxine.
         Since older persons are more vulnerable for adverse drug reactions, beneficial effects
         of genotype adjusted dosing are expected to be more apparent in this population. Therefore,
         the trial is conducted among older depressed patients starting with nortriptyline
         or venlafaxine. The cost-effectiveness of this screening will be assessed to support
         decision-making on the potential implementation of screening for 
         <i>CYP2D6</i> genotype in daily clinical practice. The trial is designed to allow reporting according
         to the CONSORT guidelines 
         <span tagx="abbrgrp">
            <span tagx="abbr">18</span>
         </span>.
      </p>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Method/Design</h2>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Study design</h3>
         </div>
         <p>The study is a multicenter randomized controlled trial across multiple old age psychiatry
            and geriatric mental health care institutions in the Netherlands. Patients will be
            recruited by their treating physician or a specialized trial nurse. The study consists
            of two parts and for both parts separate written informed consent will be obtained.
            The first part is a basic genotype screening study in which each eligible patient
            (see description in Participants below) starting with nortriptyline or venlafaxine
            will be asked permission for genotyping. Patients with a PM, IM and UM genotype will
            be selected for participation in the second (trial) part of the study. After giving
            the second informed consent, the trial entails a follow-up period of 6 weeks or longer
            in order to monitor the blood levels and adverse reactions of either nortriptyline
            or venlafaxine. A random selection of patients with an EM genotype will be allocated
            to an additional reference group (Figure 
            <div tagx="figr">1</div>). Recruitment is expected to be completed within approximately 3 years. If selected
            for the trial part of the study, eligible patients are invited for a baseline visit.
            At baseline, 2 weeks, and 4 weeks after baseline blood samples are collected to estimate
            the blood level of the drug by a ‘Dried Blood Spot’ (DBS) method. Additionally, questionnaires
            concerning adverse drug reactions, quality of life, productivity and health care use,
            and severity of depression are completed. Patients who do not complete dose-finding
            after 6 weeks will be followed for additional 2-week measurements until dose-finding
            is completed. These additional 2-week samples will be collected only for those patients
            who had a dose change 3 weeks or less prior to the moment the sample was collected,
            since it can take up to 2 to 3 weeks for PMs of nortriptyline to reach steady state
            concentration 
            <span tagx="abbrgrp">
               <span tagx="abbr">19</span>
            </span>. When the follow-up period is finished for an individual patient, the genotype information
            will be supplied to the treating physician. Ethical approval was obtained by an Independent
            Ethics Committee (RTPO-Leeuwarden-NL; file number: NL40925.099.12) and the study will
            be conducted in accordance with the Declaration of Helsinki.
            
         </p>
         <div tagx="fig">
            <div tagx="title">
               <p>Figure 1</p>
            </div>
            <caption>
               <p>Flowchart for inclusion of patients. </p>
            </caption>
            <div tagx="text">
               <p>
                  <b>Flowchart for inclusion of patients.</b>
               </p>
            </div>
            <div tagx="graphic"></div>
         </div>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Participants</h3>
         </div>
         <p>Patients 60 years or older and diagnosed with a major depression according to the
            
            <i>Diagnostic and Statistical Manual of Mental Disorders, fourth edition text revision</i> (DSM-IV TR) 
            <span tagx="abbrgrp">
               <span tagx="abbr">20</span>
            </span>, criteria (code: 296.2x or 296.3x) diagnosed by the treating physician, are eligible
            for inclusion. Patients should be starting with either nortriptyline or venlafaxine
            and competent to understand the two separate informed consent procedures. Patients
            with known liver cell damage, which in clinical practice often serves as a proxy for
            a poor hepatic function (aspartate aminotransferase and alanine aminotransferase (ASAT/ALAT)
            or gamma-glutamyl transferase (γ-GT) ≥ twice the maximal reference value), impaired
            renal function (eGFR &lt; 30 mL/minute) in combination with venlafaxine use, or currently
            using drugs influencing blood levels of nortriptyline or venlafaxine are excluded
            for trial participation. Patients using terbinafine, ketoconazole, voriconazole, kinidine,
            propafenon, cimetidine, fluoxetine, paroxetine, bupropion, duloxetine, sertraline,
            abirateron, cinacalcet, rifampicine, and ritanovir are excluded for trial participation.
            For these drugs, interactions can be expected based on pharmacy interaction monitoring
            software (G-standaard, Z-index BV, The Hague, The Netherlands), summary of product
            characteristics, and Flockhart’s interaction table 
            <span tagx="abbrgrp">
               <span tagx="abbr">21</span>
            </span>.
         </p>
         <div id="">
            <div tagx="st">
               <h4>
                  <i>CYP2D6</i> genotyping
               </h4>
            </div>
            <p>In the first part of the study, a DBS sample for genotyping will be taken at the time
               of prescription of nortriptyline or venlafaxine by means of a finger-prick 
               <span tagx="abbrgrp">
                  <span tagx="abbr">22</span>
               </span>. The sample will be sent to the Pharmacogenetic lab of the Wilhelmina Hospital Assen
               (Assen, the Netherlands), for analysis. Single nuclear polymorphism (SNPs) will be
               assessed for the *3, *4, *5, *6, *10, *17, *41 alleles, as well as duplications of
               the 
               <i>CYP2D6</i> gene. Presence of an allele that completely lacks enzyme activity (*3, *4, *5, *6
               ) paired with another allele completely lacking enzyme activity results in a PM phenotype
               prediction and in an IM phenotype prediction if paired with an allele with decreased
               enzyme activity (*10, *17, *41). Presence of only one allele lacking enzyme activity,
               or two alleles with decreased enzyme activity also results in an IM phenotype prediction.
               Duplications of the 
               <i>CYP2D6</i> gene results in an UM phenotype prediction unless it is combined with any allele
               with reduced or lacking enzyme activity. Duplications combined with any allele with
               reduced or lacking enzyme activity results in exclusion of the patient from follow-up
               because no adequate dosing advice can be given for these genotypes. After inclusion,
               genotype information will be available for randomization within 6 to 9 days.
            </p>
         </div>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Baseline</h3>
         </div>
         <p>Baseline assessment will include a severity of depression score measured by the Montgomery-Asberg
            Depression Rating Scale and measurement of symptoms which are followed-up as adverse
            events during the further trial 
            <span tagx="abbrgrp">
               <span tagx="abbr">23</span>
            </span>. In addition, comorbidities and drug use other than nortriptyline and venlafaxine
            will be collected by the Short Form Health and Labor Questionnaire 
            <span tagx="abbrgrp">
               <span tagx="abbr">24</span>
            </span>.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Randomization and allocation</h3>
         </div>
         <p>After the genotype is determined, patients with a PM, IM, or UM genotype are selected
            and randomly allocated by computer to the ‘deviating genotype-intervention arm’ (DG-I)
            or ‘deviating genotype-control arm’ (DG-C) for participation in the main study (Figure 
            <div tagx="figr">1</div>). An additional sample of patients with the EM genotype is allocated to a third ‘normal
            genotype- control’ arm (NG-C). The PM, IM and UM genotypes for 
            <i>CYP2D6</i> are expected to be found in approximately 30% of the population 
            <span tagx="abbrgrp">
               <span tagx="abbr">9</span>
            </span>. Therefore, it is expected that patients with the EM genotype will be found more
            frequently than patients with a deviating genotype. To prevent any potential time-dependent
            bias, the selection of patients with an EM genotype allocated to the NG-C arm is dependent
            on the number of patients in the other trial arms.
         </p>
         <div id="">
            <div tagx="st">
               <h4>Deviating genotype-intervention arm (DG-I)</h4>
            </div>
            <p>The DG-I arm includes patients with a PM, IM, or UM genotype. The specific genotype
               accompanied by dosing advice is directly communicated to the treating physician. This
               should preferably take place 14 days after inclusion. The dosing advice is based on
               the genotype and drug only, meaning some standard advice depending on these two variables
               is given by an automatically generated message (see Additional file 
               <div tagx="supplr">1</div>).
            </p>
         </div>
         <div id="">
            <div tagx="st">
               <h4>Deviating genotype-control arm (DG-C) and normal genotype-control arm (NG-C)</h4>
            </div>
            <p>The DG-C arm includes patients with a deviating genotype and the NG-C arm will include
               patients with a normal genotype. In contrast to patients in the intervention arm,
               the treating physician will not be informed about the genotype of patients in one
               of the control arms. Although methodologically there is a different approach for deviating
               and normal genotype patients, for the physician, patients will appears as one control
               group. This ensures that patients in the control group can have any genotype as in
               the normal population.
            </p>
         </div>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Outcomes</h3>
         </div>
         <div id="">
            <div tagx="st">
               <h4>Primary outcome</h4>
            </div>
            <p>Primary outcome will be the time needed to reach adequate blood levels of nortriptyline
               or venlafaxine, which will be determined by a DBS sample 
               <span tagx="abbrgrp">
                  <span tagx="abbr">25</span>
               </span>,
               <span tagx="abbrgrp">
                  <span tagx="abbr">26</span>
               </span>. The use of DBS for therapeutic drug monitoring is described in more depth elsewhere
               
               <span tagx="abbrgrp">
                  <span tagx="abbr">27</span>
               </span>. Blood samples will be sent to the Laboratory for Drug Analysis &amp; Toxicology of the
               Diaconessen Hospital (Meppel, the Netherlands). Advised therapeutic ranges follow
               the current Dutch Clinical Pharmacy guidelines (NVZA), indicating for nortriptyline
               levels between 50 to 150 μg/L and for venlafaxine + O-desmethylvenlafaxine between
               100 to 400 μg/L. We defined adequate drug levels as 
               <span tagx="abbrgrp">
                  <span tagx="abbr">1</span>
               </span> being within the therapeutic range and 
               <span tagx="abbrgrp">
                  <span tagx="abbr">2</span>
               </span> no dose changes during the previous 3 weeks.
            </p>
         </div>
         <div id="">
            <div tagx="st">
               <h4>Secondary outcome</h4>
            </div>
            <p>Secondary outcomes will be adverse drug reactions measured by a shorter and modified
               version of the Antidepressant Side-Effect Checklist (ASEC) 
               <span tagx="abbrgrp">
                  <span tagx="abbr">28</span>
               </span>, quality of life measured by the EuroQol 5D (EQ5D) 
               <span tagx="abbrgrp">
                  <span tagx="abbr">29</span>
               </span>, and productivity and cost of health care use measured by the Trimbos/iMTA questionnaire
               for Cost associated with Psychiatric Illness (TiC-P) 
               <span tagx="abbrgrp">
                  <span tagx="abbr">24</span>
               </span>. Severity of depression will be measured to control for possible differences between
               groups related to the severity of depression instead of the genotype-based intervention,
               by the Quick Inventory of Depressive Symptomatology Self-Reported Questionnaire (QIDS-SR)
               
               <span tagx="abbrgrp">
                  <span tagx="abbr">30</span>
               </span>. Secondary outcomes will all be measured by a telephone interview from baseline till
               endpoint, every 2 weeks, except for the side-effects. Side-effects will be assessed
               by the treating physician and will additionally be collected before start of the treatment.
               In this way we will be able to correct for symptoms of depression or other underlying
               physical diseases, which are often perceived by the patient as side-effects of the
               antidepressant 
               <span tagx="abbrgrp">
                  <span tagx="abbr">28</span>
               </span>.
            </p>
         </div>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Sample size calculation</h3>
         </div>
         <p>Based on clinical experience in the research setting it is expected that on average
            it takes 4 weeks for patients with a deviating genotype to reach adequate serum drug
            levels. It is hypothesized that time to reach adequate levels will be reduced by 50%
            (2 weeks) if we provide the screening information to the physician within 6 to 9 days.
            To obtain 90% power to detect a 50% reduction from 4 to 2 weeks (SD 3 weeks) with
            a type-1 error of 2.5% to account for multiple testing (within trial and externaltrial),
            a minimum of 48 patients per arm is needed. To account for loss to follow-up we intend
            to include at least 75 patients per arm.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Statistical analysis and report</h3>
         </div>
         <p>Reporting and analysis of the data from this trial will be in accordance with the
            CONSORT 2010 guidelines 
            <span tagx="abbrgrp">
               <span tagx="abbr">18</span>
            </span>.
         </p>
         <div id="">
            <div tagx="st">
               <h4>Baseline</h4>
            </div>
            <p>Baseline characteristics will be presented using descriptive statistics including
               means or medians for continuous variables and percentages for categorical variables.
               Analytical statistics to estimate difference between the group of patients who were
               lost to follow-up versus patients who completed the trial as well as between the different
               study arms will be determined by 
               <i>t</i>-tests or non-parametric alternatives for continuous variables and Chi-square tests
               for categorical variables.
            </p>
         </div>
         <div id="">
            <div tagx="st">
               <h4>Primary analysis</h4>
            </div>
            <p>The primary analysis will assess the mean time needed to obtain adequate drug levels.
               The first time drug blood levels are within the therapeutic range and dose is not
               increased or decreased in the following 3 weeks is the moment that is considered as
               the time needed to obtain adequate drug levels. Mean differences in time to reach
               adequate drug levels between trial groups will be estimated using the 
               <i>t</i>-test or a non-parametric alternative if not normally distributed. Analysis of variance
               (ANOVA) or Kruskal-Wallis test will be applied to test for potential differences between
               the trial groups and the external reference group.
            </p>
         </div>
         <div id="">
            <div tagx="st">
               <h4>Secondary analyses</h4>
            </div>
            <p>Secondary analysis will focus on statistical differences in median number and severity
               scores of side-effects of the drug. Since the side-effect profile is different for
               nortriptyline and venlafaxine, these analyses will be drug-specific.
            </p>
         </div>
         <div id="">
            <div tagx="st">
               <h4>Cost-effectiveness analyses</h4>
            </div>
            <p>Effects and costs will be determined from a societal perspective including both indirect
               and direct costs. Data on health care associated resource use will be collected and
               effects on productivity and quality of life (EQ5D) will be investigated. To determine
               the incremental cost-effectiveness ratio for intervention versus control strategy
               from a societal perspective, guideline unit costs will be linked to these resource
               use data. Incremental cost-effectiveness will be calculated using state-of-the-art
               methods including uncertainty analysis (bootstrapping, Fieller’s estimates), scenario
               analysis, (probabilistic) sensitivity analysis and presentation in cost-effectiveness
               acceptability curves.
            </p>
         </div>
      </div>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Discussion</h2>
      </div>
      <p>To the best of our knowledge, this is the first pragmatic randomized controlled trial
         designed to test whether 
         <i>CYP2D6</i> polymorphism genotyping among older depressed patients starting with nortriptyline
         or venlafaxine in clinical practice adds value to regular care. Results of this trial
         will generate evidence as to whether routinely-based genotype testing can reduce the
         time needed for dose-finding at the start of treatment and as a result reduce adverse
         drug reactions.
      </p>
      <p>A possible limitation of this study is that the genotype information is given to the
         physician after treatment with the antidepressant has already been started for several
         days. For the purpose of this trial, it would be ideal to give the genotype information
         before treatment has started. However, in clinical practice due to the urgency of
         the disease, time between initiating a therapy with nortriptyline or venlafaxine and
         actual start is limited. Waiting for the genotype information before starting pharmacotherapy
         could delay pharmacotherapy and is, therefore, unwanted. Nevertheless, an effect of
         genotype is still expected, because at start of treatment a low dose is generally
         prescribed. When the treating physician has to evaluate therapy and to decide if the
         dosage should be increased, the genotype information will be available 
         <span tagx="abbrgrp">
            <span tagx="abbr">31</span>
         </span>.
      </p>
      <p>Another limitation of this study is the study domain represented by a heterogeneous
         group of severely depressed patients, since the disease shows much variation in symptomatology,
         severity and co-existing psychiatric diseases like anxiety disorders and physical
         diseases, especially in secondary care 
         <span tagx="abbrgrp">
            <span tagx="abbr">32</span>
         </span>. However, a strict selection of patients who suffer from depression without the presence
         of certain comorbid physical or psychiatric disorders would exclude a lot of patients
         from this study and limit applicability of the results to daily practice. Therefore,
         inclusion is not limited by severity of depression, co-existing psychiatric diseases
         or other comorbidities. This is a common characteristic of pragmatic trials and gives
         results which are better generalizable to actual clinical practice 
         <span tagx="abbrgrp">
            <span tagx="abbr">33</span>
         </span>.
      </p>
      <p>Furthermore, the drug concentration-effect relationship for venlafaxine is still a
         subject of debate 
         <span tagx="abbrgrp">
            <span tagx="abbr">34</span>
         </span>. This is illustrated by different advised therapeutic windows. Some refer to a therapeutic
         window between 250 to 750 μg/L, whereas recent guidelines advice a therapeutic window
         between 100 to 400 μg/L, which is also incorporated in current Dutch guidelines 
         <span tagx="abbrgrp">
            <span tagx="abbr">11</span>
         </span>,
         <span tagx="abbrgrp">
            <span tagx="abbr">35</span>
         </span>. Nevertheless, current guidelines advise a smaller therapeutic window, indicating
         the need for a more accurate drug dosing. To facilitate this, genotyping may play
         an important role.
      </p>
      <p>Strengths of this study are the random allocation of subjects to receive genetic information
         that avoids incomparability of groups, strict protocolled design with regular measurements,
         and a large number of patients to detect statistically significant differences. We
         also included an external control arm (NG-C) including patients with the EM genotype.
         This ensures physicians do not know the genotype of control patients or that it deviates
         from EM.
      </p>
      <p>The overall impact of 
         <i>CYP2D6</i> screening may be underestimated in this trial, since the genotype is a lifelong characteristic
         and is, therefore, affecting the metabolism of many other drugs than the drugs studied
         in this trial. We only look at a short drug-specific time effect in this study; however,
         it is not unlikely that patients might benefit from their genotype information during
         further pharmacotherapy.
      </p>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Trial status</h2>
      </div>
      <p>The recruitment of patients started in spring 2013 and is expected to continue until
         spring 2016.
      </p>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Abbreviations</h2>
      </div>
      <p>ALT: alanine aminotransferase</p>
      <p>ANOVA: analysis of variance</p>
      <p>ASEC: Antidepressants Side-Effect Checklist</p>
      <p>AST: aspartate aminotransferase</p>
      <p>DBS: Dried Blood Spot</p>
      <p>DG-C: deviating genotype control</p>
      <p>DG-I: deviating genotype intervention</p>
      <p>DSM: 
         
         <i>Diagnostic and Statistical Manual of Mental Disorders</i>
      </p>
      <p>EQ5D: EuroQol 5D quality of life quesionnaire</p>
      <p>EM: extensive metabolizer</p>
      <p>γGT: gamma-glutamyl transferase</p>
      <p>IM: intermediate metabolizer</p>
      <p>KNMP: Royal Dutch Pharmacist Association</p>
      <p>NG-EC: normal genotype-external control</p>
      <p>MDD: major depressive disorder</p>
      <p>NVZA: Dutch Clinical Pharmacy guidelines</p>
      <p>PM: poor metabolizer</p>
      <p>QIDS-SR: Quick Inventory of Depressive Symptomatology Self-Reported Questionnaire</p>
      <p>SNRI: selective serotonin-noradrenaline reuptake inhibitor</p>
      <p>SSRI: selective serotonin reuptake inhibitor</p>
      <p>SNP: single nuclear polymorphism</p>
      <p>TCA: tricyclic antidepressant</p>
      <p>TiC-P: Cost associated with Psychiatric Illness</p>
      <p>TDM: therapeutic drug monitoring</p>
      <p>UM: ultrarapid metabolizer</p>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Competing interests</h2>
      </div>
      <p>The authors declare that they have no competing interests.</p>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Authors’ contributions</h2>
      </div>
      <p>EB, EH, MP, MB, LB, JB, TD, PJ, RK, JGM, RvM, HM, ROV, AR, HV, LV, and BW designed
         the study. EH contributed to the sample size calculation and statistical analysis.
         EB, EH and BW made two amendments to the first protocol. HM and AR facilitate the
         genotyping and JGM the determination of venlafaxine or nortriptyline in the blood
         samples. EB, HM, AR and BW wrote the standardized advice based on the genotype and
         existing guidelines for the intervention group (see Additional file 
         <div tagx="supplr">1</div>). EB drafted the manuscript, which was critically revised by EH, JB and BW. MB, LB,
         TD, RK, RvM, ROV, HV and LV coordinate enrollment of patients at clinical centers.
         All authors read and approved the final version of the manuscript.
      </p>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Additional file</h2>
      </div>
      <div tagx="suppl">
         <div tagx="title">
            <p>Additional file 1:</p>
         </div>
         <div tagx="text">
            <p>
               <b>Advice based on the Dutch KNMP’s pharmacogenetic guidelines, specified for this specific
                  study purpose with the help of experts in the field.
               </b> Description: this file contains the advice that was communicated to the treating
               physicians during the study period.
            </p>
         </div>
         <div tagx="file">
            <p>Click here for file</p>
         </div>
      </div>
   </div>
   <div tagx="bm">
      <div tagx="ack">
         <div id="">
            <div tagx="st">
               <h2>Acknowledgements</h2>
            </div>
            <p>
               <i>Funding</i>
            </p>
            <p>This study was funded by a grant from ‘Netherlands Organization for Health Research
               and Development (ZonMw, project number: 113102002) as a part of the ‘Priority Medicines
               in Elderly Program’. We acknowledge the work by Inge van Doornik, MSc, in supporting
               the organization of the logistics and implementation of the trial. We thank René Schutte,
               Ellen Brummel-Mulder, and Jolanda Paardekooper for their help in organizing the laboratory
               facilities during the trial.
            </p>
         </div>
      </div>
      <div tagx="refgrp">
         <div tagx="bibl">
            <div tagx="title">
               <p>Age and anxiety and depressive symptoms: the effect on domains of quality of life</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Brown</span>
                  <span tagx="fnm">PJ</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Roose</span>
                  <span tagx="fnm">SP</span>
               </li>
            </ul>
            <span tagx="source">Int J Geriatr Psychiatry</span>
            <span tagx="pubdate">2011</span>
            <span tagx="volume">26</span>
            <span tagx="issue">12</span>
            <span tagx="fpage">1260</span>
            <span tagx="lpage">6</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1002/gps.2675</span>
                  <span tagx="pubid">21351152</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Review of community prevalence of depression in later life</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Beekman</span>
                  <span tagx="fnm">AT</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Copeland</span>
                  <span tagx="fnm">JR</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Prince</span>
                  <span tagx="fnm">MJ</span>
               </li>
            </ul>
            <span tagx="source">Br J Psychiatry</span>
            <span tagx="pubdate">1999</span>
            <span tagx="volume">174</span>
            <span tagx="fpage">307</span>
            <span tagx="lpage">11</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1192/bjp.174.4.307</span>
                  <span tagx="pubid">10533549</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Age- and gender-specific prevalence of depression in latest-life - systematic review
                  and meta-analysis
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Luppa</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Sikorski</span>
                  <span tagx="fnm">C</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Luck</span>
                  <span tagx="fnm">T</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Ehreke</span>
                  <span tagx="fnm">L</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Konnopka</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Wiese</span>
                  <span tagx="fnm">B</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">J Affect Disord</span>
            <span tagx="pubdate">2012</span>
            <span tagx="volume">136</span>
            <span tagx="issue">3</span>
            <span tagx="fpage">212</span>
            <span tagx="lpage">21</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1016/j.jad.2010.11.033</span>
                  <span tagx="pubid">21194754</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions,
                  1990–2010: a systematic analysis for the global burden of disease study 2010
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Murray</span>
                  <span tagx="fnm">CJ</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Vos</span>
                  <span tagx="fnm">T</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Lozano</span>
                  <span tagx="fnm">R</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Naghavi</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Flaxman</span>
                  <span tagx="fnm">AD</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Michaud</span>
                  <span tagx="fnm">C</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">Lancet</span>
            <span tagx="pubdate">2012</span>
            <span tagx="volume">380</span>
            <span tagx="issue">9859</span>
            <span tagx="fpage">2197</span>
            <span tagx="lpage">223</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1016/S0140-6736(12)61689-4</span>
                  <span tagx="pubid">23245608</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Projections of global mortality and burden of disease from 2002 to 2030</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Mathers</span>
                  <span tagx="fnm">CD</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Loncar</span>
                  <span tagx="fnm">D</span>
               </li>
            </ul>
            <span tagx="source">PLoS Med</span>
            <span tagx="pubdate">2006</span>
            <span tagx="volume">3</span>
            <span tagx="issue">11</span>
            <span tagx="fpage">e442</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1371/journal.pmed.0030442</span>
                  <span tagx="pubid">17132052</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Efficacy of treatment in older depressed patients: a systematic review and meta-analysis
                  of double-blind randomized controlled trials with antidepressants
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Kok</span>
                  <span tagx="fnm">RM</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Nolen</span>
                  <span tagx="fnm">WA</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Heeren</span>
                  <span tagx="fnm">TJ</span>
               </li>
            </ul>
            <span tagx="source">J Affect Disord</span>
            <span tagx="pubdate">2012</span>
            <span tagx="volume">141</span>
            <span tagx="issue">2–3</span>
            <span tagx="fpage">103</span>
            <span tagx="lpage">15</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1016/j.jad.2012.02.036</span>
                  <span tagx="pubid">22480823</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="note">Reuben D, Herr K, Pacala J, Pollock B, Potter J, Semla T. Depression. Geriatrics at
               your fingertips. 16th ed. American Geriatrics Society; 2014.
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="note">Landelijke stuurgroep multidiciplinaire richtlijnontwikkeling in de GGZ. Dutch Guideline
               Depression (Addendum Elderly) Addendum Ouderen bij MDR derpessie. 2008.
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary
                  aspects and functional diversity
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Ingelman-Sundberg</span>
                  <span tagx="fnm">M</span>
               </li>
            </ul>
            <span tagx="source">Pharmacogenomics J</span>
            <span tagx="pubdate">2005</span>
            <span tagx="volume">5</span>
            <span tagx="issue">1</span>
            <span tagx="fpage">6</span>
            <span tagx="lpage">13</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1038/sj.tpj.6500285</span>
                  <span tagx="pubid">15492763</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic
                  variations to the phenotype of drug response
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Kirchheiner</span>
                  <span tagx="fnm">J</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Nickchen</span>
                  <span tagx="fnm">K</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Bauer</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Wong</span>
                  <span tagx="fnm">ML</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Licinio</span>
                  <span tagx="fnm">J</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Roots</span>
                  <span tagx="fnm">I</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">Mol Psychiatry</span>
            <span tagx="pubdate">2004</span>
            <span tagx="volume">9</span>
            <span tagx="issue">5</span>
            <span tagx="fpage">442</span>
            <span tagx="lpage">73</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1038/sj.mp.4001494</span>
                  <span tagx="pubid">15037866</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Hiemke</span>
                  <span tagx="fnm">C</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Baumann</span>
                  <span tagx="fnm">P</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Bergemann</span>
                  <span tagx="fnm">N</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Conca</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Dietmaier</span>
                  <span tagx="fnm">O</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Egberts</span>
                  <span tagx="fnm">K</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">Pharmacopsychiatry</span>
            <span tagx="pubdate">2011</span>
            <span tagx="volume">44</span>
            <span tagx="issue">6</span>
            <span tagx="fpage">195</span>
            <span tagx="lpage">235</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1055/s-0031-1286287</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450
                  2D6 and CYP450 2C19
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">de Leon</span>
                  <span tagx="fnm">J</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Armstrong</span>
                  <span tagx="fnm">SC</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Cozza</span>
                  <span tagx="fnm">KL</span>
               </li>
            </ul>
            <span tagx="source">Psychosomatics</span>
            <span tagx="pubdate">2006</span>
            <span tagx="volume">47</span>
            <span tagx="issue">1</span>
            <span tagx="fpage">75</span>
            <span tagx="lpage">85</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1176/appi.psy.47.1.75</span>
                  <span tagx="pubid">16384813</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="note">Hicks JK, Swen JJ, Thorn CF, Sangkuhl K, Kharasch ED, Ellingrod VL, et al. Clinical
               pharmacogenetics implementation consortium guideline for CYP2D6 and CYP2C19 genotypes
               and dosing of tricyclic antidepressants. Clin Pharmacol Ther. 2013.
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Pharmacogenetics: from bench to byte - an update of guidelines</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Swen</span>
                  <span tagx="fnm">JJ</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Nijenhuis</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">de Boer</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Grandia</span>
                  <span tagx="fnm">L</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">der Zee AH</span>
                  <span tagx="fnm">M-v</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Mulder</span>
                  <span tagx="fnm">H</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">Clin Pharmacol Ther</span>
            <span tagx="pubdate">2011</span>
            <span tagx="volume">89</span>
            <span tagx="issue">5</span>
            <span tagx="fpage">662</span>
            <span tagx="lpage">73</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1038/clpt.2011.34</span>
                  <span tagx="pubid">21412232</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Pharmacogenetics: from bench to byte</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Swen</span>
                  <span tagx="fnm">JJ</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Wilting</span>
                  <span tagx="fnm">I</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">de Goede</span>
                  <span tagx="fnm">AL</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Grandia</span>
                  <span tagx="fnm">L</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Mulder</span>
                  <span tagx="fnm">H</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Touw</span>
                  <span tagx="fnm">DJ</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">Clin Pharmacol Ther</span>
            <span tagx="pubdate">2008</span>
            <span tagx="volume">83</span>
            <span tagx="issue">5</span>
            <span tagx="fpage">781</span>
            <span tagx="lpage">7</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1038/sj.clpt.6100507</span>
                  <span tagx="pubid">18253145</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Pharmacogenetics in psychiatry - a useful clinical tool or wishful thinking for the
                  future?
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Kirchheiner</span>
                  <span tagx="fnm">J</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Seeringer</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Viviani</span>
                  <span tagx="fnm">R</span>
               </li>
            </ul>
            <span tagx="source">Curr Pharm Des</span>
            <span tagx="pubdate">2010</span>
            <span tagx="volume">16</span>
            <span tagx="issue">2</span>
            <span tagx="fpage">136</span>
            <span tagx="lpage">44</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.2174/138161210790112728</span>
                  <span tagx="pubid">20205659</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Genetic differences in cytochrome P450 enzymes and antidepressant treatment response</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Hodgson</span>
                  <span tagx="fnm">K</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Tansey</span>
                  <span tagx="fnm">K</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Dernovsek</span>
                  <span tagx="fnm">MZ</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Hauser</span>
                  <span tagx="fnm">J</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Henigsberg</span>
                  <span tagx="fnm">N</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Maier</span>
                  <span tagx="fnm">W</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">J Psychopharmacol</span>
            <span tagx="pubdate">2014</span>
            <span tagx="volume">28</span>
            <span tagx="issue">2</span>
            <span tagx="fpage">133</span>
            <span tagx="lpage">41</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1177/0269881113512041</span>
                  <span tagx="pubid">24257813</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group
                  randomised trials
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Schulz</span>
                  <span tagx="fnm">KF</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Altman</span>
                  <span tagx="fnm">DG</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Moher</span>
                  <span tagx="fnm">D</span>
               </li>
            </ul>
            <span tagx="source">PLoS Med</span>
            <span tagx="pubdate">2010</span>
            <span tagx="volume">7</span>
            <span tagx="issue">3</span>
            <span tagx="fpage">e1000251</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1371/journal.pmed.1000251</span>
                  <span tagx="pubid">20352064</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional
                  CYP2D6 genes
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Dalen</span>
                  <span tagx="fnm">P</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Dahl</span>
                  <span tagx="fnm">ML</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Bernal Ruiz</span>
                  <span tagx="fnm">ML</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Nordin</span>
                  <span tagx="fnm">J</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Bertilsson</span>
                  <span tagx="fnm">L</span>
               </li>
            </ul>
            <span tagx="source">Clin Pharmacol Ther</span>
            <span tagx="pubdate">1998</span>
            <span tagx="volume">63</span>
            <span tagx="issue">4</span>
            <span tagx="fpage">444</span>
            <span tagx="lpage">52</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1016/S0009-9236(98)90040-6</span>
                  <span tagx="pubid">9585799</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="note">American Psychiatric Association. Diagnostic and statistical manual of mental disorders
               (4th ed., text rev.). Washington, DC: Author; 2000.
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="note">Flockhart DA. Drug interactions: cytochrome P450 drug interaction table. Indiana University
               School of Medicine (2007). 2013. Available at: 
               <a href="http://medicine.iupui.edu/clinpharm/ddis/table.aspx">http://medicine.iupui.edu/clinpharm/ddis/table.aspx</a>. Accessed 8 August 2014
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Application of dried blood spot sampling combined with LC-MS/MS for genotyping and
                  phenotyping of CYP450 enzymes in healthy volunteers
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">de Boer</span>
                  <span tagx="fnm">T</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Wieling</span>
                  <span tagx="fnm">J</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Meulman</span>
                  <span tagx="fnm">E</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Reuvers</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Renkema</span>
                  <span tagx="fnm">G</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">den Daas</span>
                  <span tagx="fnm">I</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">Biomed Chromatogr</span>
            <span tagx="pubdate">2011</span>
            <span tagx="volume">25</span>
            <span tagx="issue">10</span>
            <span tagx="fpage">1112</span>
            <span tagx="lpage">23</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1002/bmc.1580</span>
                  <span tagx="pubid">21287583</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>A new depression scale designed to be sensitive to change</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Montgomery</span>
                  <span tagx="fnm">SA</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Asberg</span>
                  <span tagx="fnm">M</span>
               </li>
            </ul>
            <span tagx="source">Br J Psychiatry</span>
            <span tagx="pubdate">1979</span>
            <span tagx="volume">134</span>
            <span tagx="fpage">382</span>
            <span tagx="lpage">9</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1192/bjp.134.4.382</span>
                  <span tagx="pubid">444788</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Hakkaart-Van Roijen</span>
                  <span tagx="fnm">L</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">van Straten</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Donker</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Tiemens</span>
                  <span tagx="fnm">B</span>
               </li>
            </ul>
            <span tagx="source">Manual Trimbos/iMTA questionnaire for costs asscociated with psychiatric ilness (TiC-P)
               (in Dutch)
            </span>
            <span tagx="pubdate">2002</span>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Determination of venlafaxine and O-desmethylvenlafaxine in dried blood spots for TDM
                  purposes, using LC-MS/MS
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Berm</span>
                  <span tagx="fnm">EJ</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Brummel-Mulder</span>
                  <span tagx="fnm">E</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Paardekooper</span>
                  <span tagx="fnm">J</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Hak</span>
                  <span tagx="fnm">E</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Wilffert</span>
                  <span tagx="fnm">B</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Maring</span>
                  <span tagx="fnm">JG</span>
               </li>
            </ul>
            <span tagx="source">Anal Bioanal Chem</span>
            <span tagx="pubdate">2014</span>
            <span tagx="volume">406</span>
            <span tagx="issue">9–10</span>
            <span tagx="fpage">2349</span>
            <span tagx="lpage">53</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1007/s00216-014-7619-9</span>
                  <span tagx="pubid">24493333</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="note">Berm EJJ, Paardekooper J, Brummel-Mulder E, Hak E, Wilffert B, Maring JG. A simple
               dried bloodspot method for therapeutic drug monitoring of the tricyclic antidepressants
               amitriptyline, nortriptyline, imipramine, clomipramine, and their active metabolites
               using LC-MS/MS. Talanta Advance online publication. doi:10.1016/j.talanta.2014.10.041.
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Dried blood spot methods in therapeutic drug monitoring: methods, assays, and pitfalls</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Edelbroek</span>
                  <span tagx="fnm">PM</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">van der Heijden</span>
                  <span tagx="fnm">J</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Stolk</span>
                  <span tagx="fnm">LM</span>
               </li>
            </ul>
            <span tagx="source">Ther Drug Monit</span>
            <span tagx="pubdate">2009</span>
            <span tagx="volume">31</span>
            <span tagx="issue">3</span>
            <span tagx="fpage">327</span>
            <span tagx="lpage">36</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1097/FTD.0b013e31819e91ce</span>
                  <span tagx="pubid">19349929</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Adverse reactions to antidepressants</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Uher</span>
                  <span tagx="fnm">R</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Farmer</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Henigsberg</span>
                  <span tagx="fnm">N</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Rietschel</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Mors</span>
                  <span tagx="fnm">O</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Maier</span>
                  <span tagx="fnm">W</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">Br J Psychiatry</span>
            <span tagx="pubdate">2009</span>
            <span tagx="volume">195</span>
            <span tagx="issue">3</span>
            <span tagx="fpage">202</span>
            <span tagx="lpage">10</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1192/bjp.bp.108.061960</span>
                  <span tagx="pubid">19721108</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="note">EuroQol - a new facility for the measurement of health-related quality of life. The
               EuroQol Group. Health Policy. 1990;16(3):199–8
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>The 16-item quick inventory of depressive symptomatology (QIDS), clinician rating
                  (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic
                  major depression
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Rush</span>
                  <span tagx="fnm">AJ</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Trivedi</span>
                  <span tagx="fnm">MH</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Ibrahim</span>
                  <span tagx="fnm">HM</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Carmody</span>
                  <span tagx="fnm">TJ</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Arnow</span>
                  <span tagx="fnm">B</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Klein</span>
                  <span tagx="fnm">DN</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">Biol Psychiatry</span>
            <span tagx="pubdate">2003</span>
            <span tagx="volume">54</span>
            <span tagx="issue">5</span>
            <span tagx="fpage">573</span>
            <span tagx="lpage">83</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1016/S0006-3223(02)01866-8</span>
                  <span tagx="pubid">12946886</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Utility and adoption of CYP2D6 and CYP2C19 genotyping and its translation into psychiatric
                  clinical practice
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Jurgens</span>
                  <span tagx="fnm">G</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Jacobsen</span>
                  <span tagx="fnm">CB</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Rasmussen</span>
                  <span tagx="fnm">HB</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Werge</span>
                  <span tagx="fnm">T</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Nordentoft</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Andersen</span>
                  <span tagx="fnm">SE</span>
               </li>
            </ul>
            <span tagx="source">Acta Psychiatr Scand</span>
            <span tagx="pubdate">2012</span>
            <span tagx="volume">125</span>
            <span tagx="issue">3</span>
            <span tagx="fpage">228</span>
            <span tagx="lpage">37</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1111/j.1600-0447.2011.01802.x</span>
                  <span tagx="pubid">22128793</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Psychiatric disorders in the elderly</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Skoog</span>
                  <span tagx="fnm">I</span>
               </li>
            </ul>
            <span tagx="source">Can J Psychiatry</span>
            <span tagx="pubdate">2011</span>
            <span tagx="volume">56</span>
            <span tagx="issue">7</span>
            <span tagx="fpage">387</span>
            <span tagx="lpage">97</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">21835102</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>The case for practical clinical trials in psychiatry</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">March</span>
                  <span tagx="fnm">JS</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Silva</span>
                  <span tagx="fnm">SG</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Compton</span>
                  <span tagx="fnm">S</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Shapiro</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Califf</span>
                  <span tagx="fnm">R</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Krishnan</span>
                  <span tagx="fnm">R</span>
               </li>
            </ul>
            <span tagx="source">Am J Psychiatry</span>
            <span tagx="pubdate">2005</span>
            <span tagx="volume">162</span>
            <span tagx="issue">5</span>
            <span tagx="fpage">836</span>
            <span tagx="lpage">46</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1176/appi.ajp.162.5.836</span>
                  <span tagx="pubid">15863782</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>PharmGKB summary: venlafaxine pathway</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Sangkuhl</span>
                  <span tagx="fnm">K</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Stingl</span>
                  <span tagx="fnm">JC</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Turpeinen</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Altman</span>
                  <span tagx="fnm">RB</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Klein</span>
                  <span tagx="fnm">TE</span>
               </li>
            </ul>
            <span tagx="source">Pharmacogenet Genomics</span>
            <span tagx="pubdate">2014</span>
            <span tagx="volume">24</span>
            <span tagx="issue">1</span>
            <span tagx="fpage">62</span>
            <span tagx="lpage">72</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1097/FPC.0000000000000003</span>
                  <span tagx="pubid">24128936</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Relevant issues in the monitoring and the toxicology of antidepressants</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Wille</span>
                  <span tagx="fnm">SM</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Cooreman</span>
                  <span tagx="fnm">SG</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Neels</span>
                  <span tagx="fnm">HM</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Lambert</span>
                  <span tagx="fnm">WE</span>
               </li>
            </ul>
            <span tagx="source">Crit Rev Clin Lab Sci</span>
            <span tagx="pubdate">2008</span>
            <span tagx="volume">45</span>
            <span tagx="issue">1</span>
            <span tagx="fpage">25</span>
            <span tagx="lpage">89</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1080/10408360701713112</span>
                  <span tagx="pubid">18293180</span>
               </div>
            </div>
         </div>
      </div>
   </div>
</html>